Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Think About Your Approach to Dry Eye Disease Treatment



ReachMD Healthcare Image

How can clinicians approach treating their patients with dry eye disease (DED)? And why is it important to treat dry eye disease early in the patient journey?

Please See

Indication and Important Safety Information

  • Sponsored by

  • Overview

    This episode features Margeurite McDonald, MD of OCLI Vision in Rockville Centre, New York; Paul Karpecki, OD of Kentucky Eye Institute in Lexington, KY; Walter Whitley, OD of Virginia Eye Consultants in Norfolk, VA; and Eric Donnenfeld, MD of OCLI Vision, Garden Centre, NY. These physicians are consultants for Novartis and compensated for their time.

    On average, patients with dry eye symptoms use 3.3 different brands of artificial tears.1*  This episode discusses what clinicians need to know when treating their patients with DED.

    *Multi-Sponsor Surveys, Inc 2022; among patients reporting use of non-Rx artificial tears (respondents=509, weighted base-803)

    Survey Statement: The survey instrument is unvalidated and reports data from online consumer panels. The results of the survey have not been published and are not intended to provide a clinical assessment of dry eye disease or the safety or efficacy of any therapeutic options for this condition. All sample surveys are subject to recognized limitations including possible sampling error. 


    1. Data on file. Multi-Sponsor Surveys, Inc. 2022.


    Sponsored by Novartis Pharmaceuticals Corporation

    4/23     273325


    Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).


    • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
    • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
    • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
    • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
    • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

    Click here for Full Prescribing Information.

    Study Methodology: The 2022 Syndicated Study of Dry Eye Sufferers, 18th survey in a trended series from 2002-2022, uses self-reported consumer research that focuses on both self-diagnosed and physician-diagnosed dry eye disease in the United States. The survey was conducted through online panel interviews. The key research objectives of the study included: Dry eye symptoms and severity, Rx and OTC treatments used, brand awareness, use and satisfaction, and attitude toward dry eye treatments. Data presented is for 2022. 

    Phase I: Conducted from January 5 to 17, 2022 among a national sample of adults 18 years and older (n=1039). Sample was weighted by key demographic variables provided by US Census profiles.

    Phase II: Conducted from June 6 to 30, 2022 among a national sample of adults 18 years or older who self-reported dry eye symptoms regulary (n=766). Sample was weighted by key demographic variables to match the profile of dry eye sufferers found in the Phase I sample. 

    Limitations: This is syndicated, primary self-reported consumer research, utilizing online consumer panels and is not meant to be a clinical assessment of dry eye disease. All sample surveys are subject to sampling error. The size of such sampling errors depends largely on the number of interviews. 

    Pivotal trial data
    The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0-4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0-100).

    Effects on symptoms of dry eye disease: A larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials.

    Effects on signs of dry eye disease: At day 84, larger reduction in ICSS favoring Xiidra was observed in 3 of 4 studies.

Schedule22 Sep 2023